The issuance of US Patent 11,247,902 B2 further strengthens JanOne Inc.’s intellectual patent portfolio.
LA VEGAS, June 7, 2022 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on the development of drugs with non-addictive and analgesic properties, today announced that a patent has been issued covering a method of enhancing of nerve function using JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral arterial disease (PAD), a vascular disease that affects more than 8.5 million people in the United States and more than 60 million people worldwide. world.
“This patent further protects JanOne Inc.’s product for use in the treatment of PAD by expanding the use of JAN101 to treat nerve damage caused by microvascular disease,” said Dr. Tony GiordanoScientific Director of JanOne Inc. “Microvascular disease is a major problem for patients with PAD: it leads to restriction of blood flow in the affected limb, which in turn leads to nerve damage and severe pain. Recent studies have in fact suggested that PAD is a microvascular disease, hence the observation that JAN101 improves microvascular and nerve function is crucial in the treatment of this disease.”
dr. Amol Carepain physician and JanOne’s Chief Medical Officer, added, “We believe that nerve damage plays a major role in promoting pain and therefore investigated whether JAN101 could improve nerve sensory velocity and nerve sensory conductance in a previous trial I supervised. Our previous studies showed that JAN101 improved nerve conduction velocity, which leads us to believe that it may not only improve pain, but also improve nerve function.
This pain treatment method was co-discovered by Dr. Christopher Kevil, vice chancellor for research and dean of the School of Graduate Studies at LSU Health Shreveport. This newly approved patent is owned by LSU Health Shreveport and exclusively licensed to JanOne Inc. This is the latest United States patent to be issued under JanOne’s Inc. PA and pain development program.
This press release contains statements that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to whether JAN101 will address PAD, the timing of commencement clinical trials, that the FDA will allow approval through a 505(b)(2) pathway, that upon approval JAN101 will immediately disrupt the PAD market, and other statements including words such as “continue” , “expect”, “intend”, “will”, “hope”, “should”, “will”, “may”, “potential” and other similar expressions. These statements reflect JanOne Inc.’s current view regarding future events, are subject to risks and uncertainties, and are necessarily based on a number of estimates and assumptions which, while considered reasonable by JanOne Inc. ., are inherently subject to significant business changes. , uncertainties and economic, competitive, political and social hazards. Many factors could cause the actual results, performance or achievements of JanOne Inc. to be materially different from any future results, performance or achievements described in this press release. These factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”).
Should one or more of these risks or uncertainties materialize, or should the assumptions set forth in the section titled “Risk Factors” in JanOne Inc.’s filings with the United States Securities and Exchange Commission underlying such statements prospective prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne Inc. does not intend and undertakes no obligation to update these forward-looking statements, except as required by law. JanOne Inc. cannot guarantee that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty therein.
About JanOne Inc.
JanOne Inc. is a unique Nasdaq-listed company that provides innovative and actionable solutions that it believes can help end the opioid crisis. JanOne Inc. is dedicated to funding resources for innovation, technology, and education to find a key solution to the national opioid epidemic, which is one of the nation’s deadliest and most widespread. of the country’s history. The company continues to operate its historic business – ARCA Recycling – under its current brand. JanOne Inc’s subsidiary, ARCA Recycling, recycles appliances by providing turnkey recycling and replacement services to utilities and other energy efficiency program sponsors. Please visit www.janone.com for more information.
Investor relations and media contact
1 (800) 400-2247
Show original content to download multimedia:https://www.prnewswire.com/news-releases/janone-inc-announces-the-issuance-of-us-patent-covering-a-method-of-improving-nerve-function-using-jan101-301561798. html
SOURCE JanOne Inc.